In the past few weeks, the European Commission provided marketing authorization for biosimilars of denosumab and omalizumab, as well as an ophthalmic formulation of bevacizumab.
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
Outlook Therapeutics, Inc. (NASDAQ:OTLK – Free Report) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Outlook Therapeutics in a research report issued to clients and investors on Friday, May 17th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($1.00) for the quarter. HC […]
HC Wainwright reissued their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK – Free Report) in a report published on Friday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock. HC Wainwright also issued estimates for Outlook Therapeutics’ Q1 2025 earnings at ($1.00) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 […]